Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClaritevCTEV -6.85%57 EV-to-EBITDA is 10.83 as of Jul. 23, 2026, which is 13% below its 10-year median of 12.40. GuruFocus rates CTEV with a GF Score™ of 57/100 and a GF Value™ of $31.35 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Claritev ranks better than 50.99% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Claritev's enterprise value is $5,116.0 Mil.
Claritev's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $472.6 Mil. Therefore, Claritev's EV-to-EBITDA for today is 10.83.
The historical rank and industry rank for Claritev's EV-to-EBITDA or its related term are showing as below:
CTEV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.31 Med: 12.4 Max: 805.12
Current: 10.83
During the past 8 years, the highest EV-to-EBITDA of Claritev was 805.12. The lowest was -10.31. And the median was 12.40.
CTEV's EV-to-EBITDA is ranked better than 50.99% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 10.96
vs CTEV: 10.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Claritev (NYSE:CTEV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Claritev's share price for today is $23.27.
Claritev's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Claritev's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Claritev's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Claritev EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Claritev's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Claritev's EV-to-EBITDA falls into.
Claritev's current Enterprise Value is $5,116.0 Mil.
Claritev's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $472.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Claritev (CTEV) has a EV-to-EBITDA of 10.83 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Claritev. This is 13% below median its historical median of 12.40. According to the industry distribution chart, Claritev ranks #248 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 49%.
Is Claritev's EV-to-EBITDA too high?
Claritev's current EV-to-EBITDA of 10.83 is 13% below median its 10-year median of 12.40. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.96. Claritev's value of 10.83 is 1.2% below this industry median. Based on the distribution chart, Claritev ranks #248 out of 506 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Claritev has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Claritev's EV-to-EBITDA compare to MDRX and EVH?
According to the Healthcare Providers & Services industry distribution chart, Claritev ranks #248 out of 506 companies for EV-to-EBITDA. This puts Claritev in the upper half of its industry. The industry median EV-to-EBITDA is 10.96. Claritev's value of 10.83 is 1.2% below this benchmark. While the company's 10-year median is 12.40 vs. the industry median of 10.96, Claritev has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.96, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Claritev's current EV-to-EBITDA of 10.83 is 1.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Claritev. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Claritev's current EV-to-EBITDA is 10.83, which is 13% below median its own 10-year median of 12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Claritev stock overvalued right now?
Based on GuruFocus' analysis, Claritev (CTEV) is currently considered Modestly Undervalued. The stock's GF Value™ is $31.35, compared to a current price of $23.27 — trading 25.8% below its estimated fair value. The current EV-to-EBITDA is 10.83, which is 13% below median its 10-year median of 12.40 and 1.2% below the Healthcare Providers & Services industry median of 10.96. Claritev's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Claritev (CTEV), the current EV-to-EBITDA is 10.83 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Claritev (CTEV) Overvalued in 2026?
Based on GuruFocus' analysis, Claritev stock appears to be undervalued.
The current stock price of $23.27 is trading 25.8% below its estimated GF Value™ of $31.35.
GuruFocus considers Claritev to be Modestly Undervalued.
Key valuation signals for CTEV:
EV-to-EBITDA: 10.83 (13% below median its 10-year median of 12.40)
GF Value™: $31.35 vs. price of $23.27 (25.8% below fair value)
Industry Position: 1.2% below the Healthcare Providers & Services median (#248 of 506)
No single metric tells the full story. See the CTEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
57GF Score
Get the complete analysis for CTEV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTEV has been successfully added to your 
